Welcome to our dedicated page for Invizyne Technologies SEC filings (Ticker: IZTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Invizyne Technologies’ enzyme-dense disclosures can feel like running a lab experiment without the protocol. Patent claims for cell-free “exozymes”, grant-tied milestones, and multi-layer R&D expenses hide in footnotes across the annual report. If you have ever searched “Invizyne Technologies SEC filings explained simply” or wondered where to track “Invizyne Technologies insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI solves it. Our engine reads every Invizyne Technologies quarterly earnings report 10-Q filing, each 8-K material events explained, and the full annual report 10-K simplified in seconds—highlighting cash-burn trends, new patent issuances, and sustainability metrics. Need “Invizyne Technologies Form 4 insider transactions real-time”? You’ll get instant alerts the moment an executive files. Prefer narrative? Our AI-powered summaries translate biochemical jargon into plain English, showing how enzyme pathway efficiency or government grant milestones affect the bottom line.
Whether you’re analyzing “Invizyne Technologies earnings report filing analysis,” comparing segment spend, or drilling into “Invizyne Technologies proxy statement executive compensation,” the complete archive is here—10-Q, 10-K, 8-K, S-1, DEF 14A, and more. Monitor “Invizyne Technologies executive stock transactions Form 4,” follow R&D capitalization trends, or export data for modeling. Real-time updates from EDGAR, expert commentary, and AI summaries ensure you never miss the next breakthrough—or the next dilution risk—hidden inside the fine print.
eXoZymes Inc. reported no revenue for the quarter and a six-month net loss of $4,216,707, or $0.50 per share, driven by increased R&D and G&A spending. Cash and cash equivalents totaled $6,985,858 at June 30, 2025, down from $9.72 million at year-end 2024, and working capital was approximately $6,314,087. The company offset research costs with government grants but grant receivables fell to $257,407.
The company raised net IPO proceeds of $15,206,543 in November 2024 and used funds for operations and debt repayment. Management disclosed substantial doubt about going concern and identified a material weakness in internal controls. Subsequent events include a July 1, 2025 NSF-related industrial partnership award (company share $3.0M) and board approval of an expanded 2025 equity incentive plan.
Invizyne Technologies Inc. ("IZTC") has filed Amendment No. 1 to its definitive proxy statement (Form DEFR14A) to correct the proxy card for Proposal 1, the election of directors. The updated card now offers shareholders the standard choices of "For All," "Withhold All," or "For All Except," and explains how to withhold authority for specific nominees.
The company notes that proxy materials have not yet been distributed, so investors will receive only the corrected version, avoiding the need for multiple or color-coded cards. No other proposals, financial metrics, or strategic items were affected by this administrative update.
eXoZymes Inc. (symbol: IZTC) has filed its Definitive Proxy Statement (Schedule 14A) for the 2025 Annual Meeting of Shareholders. The meeting will be held virtually on July 25, 2025 at 1:00 p.m. Pacific Time via www.virtualshareholdermeeting.com/EXOZ2025; in-person attendance is not permitted. Shareholders of record at the close of business on June 9, 2025 are entitled to vote, and proxy materials will be mailed or otherwise made available on or about June 20, 2025.
The proxy lists five voting items:
- Proposal 1: Election of six directors to serve until the 2026 AGM.
- Proposal 2: Non-binding advisory vote on 2025 executive compensation (say-on-pay).
- Proposal 3: Advisory vote on the frequency of future say-on-pay resolutions, with the Board favoring a three-year cycle.
- Proposal 4: Approval of the new 2025 Performance Equity Plan.
- Proposal 5: Ratification of RBSM LLP as independent registered public accounting firm for FY 2025.
The Board of Directors recommends a “FOR” vote on all proposals, including the adoption of the equity plan and three-year say-on-pay frequency. No additional matters are expected, but any other proper business may be transacted.
The filing is routine in nature, with no financial performance data, mergers, or capital-raising activities disclosed. Key governance items include detailed information on board structure, risk oversight, director independence, compensation philosophy, and a clawback policy.
FAQ
What is the current stock price of Invizyne Technologies (IZTC)?
What is the market cap of Invizyne Technologies (IZTC)?
